Drug Profile
Research programme: glioma therapeutics - Inhibetex Therapeutics
Latest Information Update: 12 Jan 2011
Price :
$50
*
At a glance
- Originator Inhibetex Therapeutics
- Class
- Mechanism of Action Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glioma